Skip to main content

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 618777. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46511, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/714836/Champions-Oncology-to-Announce-First-Quarter-Financial-Results-on-Thursday-September-8-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  256.02
+11.80 (4.83%)
AAPL  267.53
-2.84 (-1.05%)
AMD  257.93
+1.81 (0.71%)
BAC  53.10
-0.35 (-0.65%)
GOOG  283.18
+1.36 (0.48%)
META  647.53
-0.82 (-0.13%)
MSFT  518.00
+0.19 (0.04%)
NVDA  210.71
+8.22 (4.06%)
ORCL  258.08
-4.53 (-1.72%)
TSLA  469.44
+12.88 (2.82%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.